)
)
Spyre Therapeutics Inc Investor Relations Material
Latest events
M&A Announcement
Spyre Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Spyre Therapeutics Inc
Access all reports
Spyre Therapeutics Inc., previously known as Aeglea BioTherapeutics, is a clinical-stage biotechnology company. It specializes in developing therapeutics for inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn's disease. The company's focus is on creating novel and proprietary monoclonal antibody product candidates designed to address unmet needs in IBD care. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Cristiano Amon: Qualcomm's 5G Specialist CEO
Cristiano Amon, Qualcomm CEO, has spent two decades at the company while taking on several roles, developing both technical and business expertise.
16 Sep 2024
)
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
)
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Ticker symbol
SYRE
Country
🇺🇸 United States